Experience with ospemifene in a patient with vulvovaginal atrophy and dyslipidemia: a case study

Article Page

Abstract

The changes that occur in sex hormone levels, body composition, and lipid/lipoprotein levels during the menopause transition, together with vascular remodeling, increase the risk of cardiovascular disease (CVD) in postmenopausal women. Any treatments prescribed for concomitant conditions during menopause should not exacerbate CVD risk factors. Ospemifene is the first non-hormonal, non-estrogenic drug approved to treat moderate-to-severe vulvovaginal atrophy (VVA), a component of genitourinary syndrome of menopause, in women unsuited to receive vaginal estrogen therapy. This case study reports the experience of a postmenopausal woman with VVA who required escalation from local therapy and presented CVD risk factors (family history and hypertension). During the first 6 months of ospemifene treatment, and before initiating concomitant simvastatin for persistently elevated total cholesterol concentrations, improvements were observed in several lipid parameters (decreases of 11% in total cholesterol, 16% in low density lipoprotein cholesterol, and 15% in triglycerides) which may have been attributable at least in part to ospemifene. Improvements in lipid parameters during ospemifene treatment for VVA may contribute toward reducing long-term CVD risk.

Keywords: dyslipidemia, ospemifene, vulvar and vaginal atrophy.

Citation: González Rodríguez SP. Experience with ospemifene in a patient with vulvovaginal atrophy and dyslipidemia: a case study. Drugs in Context 2020; 9: 2020-3-5. DOI: 10.7573/dic.2020-3-5

Contributions: The author meets the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, takes responsibility for the integrity of the work as a whole, and has given her approval for this version to be published.

Disclosure and potential conflicts of interest: Dr. González Rodríguez reports grants from Pfizer, grants from Amgen, grants from Gedeon Richter, grants from Exeltis, grants from Bayer, grants from MSD, grants from Procare Health, grants and personal fees from Shionogi, grants from Serelys, and personal fees from Mylan, outside the submitted work. The author has also provided scientific support to Shionogi Spain by lecturing and/or taking part in Advisory Board meetings organized by Shionogi (Madrid, Spain). The author’s time was compensated by Shionogi Spain according to local codes of practice. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/05/dic.2020-3-5-COI.pdf

Acknowledgements: Medical writing assistance was provided by Jon Monk and Kerry Dechant on behalf of Content Ed Net (Madrid, Spain). This article forms part of a Special Issue. All authors contributed to developing this Special Issue by sharing their experience with the benefit of patients in mind. The publication is expected to benefit gynecologists in their daily clinical practice by increasing knowledge and expertise.

Funding declaration: Medical writing assistance was funded by Shionogi (Madrid, Spain). This article forms part of a Special Issue funded by Shionogi (Madrid, Spain).

Copyright: Copyright © 2020 González Rodríguez SP. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2020 González Rodríguez SP. https://doi.org/10.7573/dic.2020-3-5. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/experience-with-ospemifene-in-a-patient-with-vulvovaginal-atrophy-and-dyslipidemia:-a-case-study/

Correspondence: Silvia Pilar González Rodríguez, Policlínico HM Gabinete Velázquez, Calle Velázquez, 25, Calle Jorge Juan 19, 28001 Madrid, Spain. spgonzalez@hmhospitales.com

Provenance: submitted; externally peer reviewed.

Submitted: 20 March 2020; Peer review comments to author: 22 April 2020; Revised manuscript received: 20 May 2020; Accepted: 21 May 2020; Publication date: 1 July 2020.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF